Form 4: NeuroPace Director Lisa Andrade Receives Equity Grant

Director Lisa Andrade acquired 2,890 shares of common stock and 5,368 stock options as part of a standard equity compensation grant.

Summary

• Director Lisa Andrade was granted 2,890 shares of common stock on June 5, 2026.
• The director also received 5,368 stock options with an exercise price of $15.74.
• Both the common stock and the stock options vest in twelve equal consecutive monthly installments, contingent upon continuous service.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which is neutral in terms of market impact.

Positives

• Equity-based compensation aligns the interests of the director with those of the shareholders.

Negatives

• The issuance of new equity results in minor dilution to existing shareholders.

Risks

• Vesting is subject to the director's continuous service, creating a dependency on personnel retention.

Future Outlook

The equity grants are subject to a 12-month vesting schedule, indicating a commitment to the company's long-term governance.

Industry Context

StockSavvy.ai notes that equity grants to directors are standard corporate governance practices designed to incentivize long-term oversight and strategic alignment in the medical device sector.

Comparison to Industry Standards

• The use of monthly vesting schedules is consistent with standard equity compensation practices for board members in the healthcare technology industry.

Stakeholder Impact

• Minor dilution for existing shareholders due to the issuance of new equity.

Next Steps

• Vesting of shares and options in twelve equal monthly installments.

Key Dates

Keywords

NeuroPace, NPCE, Form 4, Insider Trading, Equity Compensation, Director Compensation